GBI Research, Sep 2011, Pages: 153
trends. In addition, the report also analyzes the top 20 pharmaceuticalcompanies, with respect to the licensing agreement activities.
The report is built using data and information sourced from
Business Insights, June 2011, Pages: 153
The report reviews the key trends in pharmaceuticallicensing, examining deal volumes, values and structure. Therapeutic focus is also covered along with detailed profiles of the strategies of 10
CBR Pharma Insights, Jan 2011, Pages: 55
activity and how those trends support company growth
- Identify who the leading companies are from an in-license & out-license point of view and if they are keeping to their overall corporate strategy
GBI Research, April 2011, Pages: 105
, the report also analyzes the top 10 biotech companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary
Business Insights, June 2006, Pages: 116
to be driving growth in licensingactivity over the past five years... " PharmaceuticalLicensingStrategies
Executive Summary
Introducing pharmaceuticallicensingLicensingtrendsLicensing process
GBI Research, Dec 2011, Pages: 76
the benchmarking of topcompanies, key trends on mergers and acquisitions, and licensing agreements involving pharmaceutical packaging.
Global Pharmaceutical Packaging Industry to Record Growth with Rapid Expansion
Decision Resources, Inc., Oct 2011 Licensingstrategies have never been more important to the pharmaceutical industry. Companies are competing on multiple fronts; they are inlicensing or acquiring innovative new drug candidates
GBI Research, Aug 2011, Pages: 108
of research and development (R&D) operations from major companies into India, the pharmaceutical industry is going to experience a major trend of mergers and acquisitions. Although many pharmaceutical giants have had
GBI Research, Feb 2010, Pages: 85
analysis by a team of industry experts.
Scope
The scope of this report includes:
- Analysis and data on LCM activities of top twenty pharmaceuticalcompanies including Roche, Bayer, GSK, and Pfizer
Datamonitor, March 2010, Pages: 114
-Assessment of drug discovery and technology deals made by the top 10 pharmaceuticalcompanies during 2008-09
Highlights
The number of in-licensing deals in 2009 increased by 12% over 2008, confirming
GBI Research, Dec 2009, Pages: 62
and developmental issues are also addressed. The report provides an in-depth analysis of the competitive landscape, including the benchmarking of topcompanies, key trends on mergers and acquisitions, and licensing
Decision Resources, Inc., June 2010, Pages: 33
in 2009 was lower than many observers expected, biotech companies continued to merge and be acquired. What are the current trends in pharma-biotech and biotech-biotech M&As? What factors drove M&A activity
Business Insights, Aug 2002
studies and executive interviews, the author provides a comprehensive guide to how best to maximize the returns on licensingactivity.
Equally valuable for pharmaceuticalcompanies, biotechnology
JZMed Inc., Oct 2011, Pages: 215
innovation, extensive outsourcing and integrated virtual operation
- New development trends of global pharmaceutical outsourcing
- New strategies currently implemented by major pharma companies
- New
JZMed Inc., April 2010, Pages: 208
Market – Deciphering Major Pharma Companies’ China Strategy” analyzed, both in detail and in depth, the whole spectrum of the activities of world top ten major pharma companies in the Chinese market. It revealed
JZMed Inc., May 2011, Pages: 230
of combined market share of top ten major pharma companies in Chinese pharmaceutical market
Table 28. Summary of main activities of multinational pharma companies in China
Table 29. Development history, current
NeuroInsights, May 2011, Pages +: 500
including drugs, devices and diagnostics
- 12 most active neurotech venture capital firms profiled with investments by market segment and U.S. neurotech venture capital trends (1999-Q12011)
- Neurotech IPOs
